Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Healthcare Biotechnology
Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Trillium Therapeutics Inc. > News
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(100)
•••
Comment by CleverInvestor2on Feb 27, 2020 11:44pm
175 Views
Post# 30744753

RE:News

RE:News
GriffMac wrote:

Trillium Therapeutics (NASDAQ:TRIL) has jumped 43.6% postmarket after reports that Gilead Sciences approached Forty Seven (NASDAQ:FTSV) with a takeover offer.

Trillium is working on a medicine similar to that in Forty Seven's lead program (magrolimab), a monoclonal antibody against the CD47 receptor.



Forty Seven is valued at about 2.3Billion.....
Trillium has "much better medicine than our competitors" so.....

I understand that Trillium is still in development and proving their drug.... but if all goes well, they'll be worth much more then Forty Seven.... and Trillium's market cap is nowhere near 2.3Billion!!!
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities